Regulatory science explained
Not All AI Is Created Equal
The AI diagnostics market is crowded. Dozens of companies claim their algorithms can detect diabetic retinopathy, identify lesions, or flag abnormal scans. But there is a meaningful — and often misunderstood — distinction between AI tools that assist human reviewers and AI systems that are cleared to operate autonomously.
What the FDA Reviews
When the FDA evaluates an autonomous AI diagnostic device, it scrutinizes the clinical evidence package with the same rigor applied to any Class II medical device. This means large-scale prospective trials, pre-specified performance thresholds, subgroup analyses across demographic variables, and a demonstrated safety profile for the intended use population.
For EyeArt, FDA clearance under the 510(k) pathway was supported by a multi-center clinical trial enrolling hundreds of patients across diverse healthcare settings. The agency specifically reviewed performance data for the autonomous use case — meaning results delivered without a clinician reviewing the image.
Why Autonomous Clearance Matters
Clearance for autonomous operation is not a technicality. It is the regulatory foundation that allows a health system to deploy EyeArt in a primary care office and deliver a result to a patient without an ophthalmologist in the loop. Without it, AI screening tools can only function as decision support — useful, but unable to replace the specialist referral model that limits access.
A High Bar That Protects Patients
The FDA's rigorous review process exists to protect patients. For clinicians considering autonomous AI screening, clearance status is one of the most important questions to ask. It signals that the evidence has been independently reviewed, the performance claims are substantiated, and the system is safe for its intended clinical use.